NASDAQ:CCCC

C4 Therapeutics Stock Earnings Reports

etoro logo Buy CCCC
*Your capital is at risk
$4.12
-0.0300 (-0.723%)
At Close: Jun 22, 2026

C4 Therapeutics Earnings Calls

Mar 31, 2026
-$0.200 (20.20%)
Release date May 12, 2026
EPS estimate -$0.251
EPS actual -$0.200
EPS Surprise 20.20%
Revenue estimate 4.417M
Revenue actual 6.2M
Revenue Surprise 40.38%
Dec 31, 2025
-$0.180 (41.94%)
Release date Feb 26, 2026
EPS estimate -$0.310
EPS actual -$0.180
EPS Surprise 41.94%
Revenue estimate 5.395M
Revenue actual 11.016M
Revenue Surprise 104.20%
Sep 30, 2025
-$0.440 (6.38%)
Release date Nov 06, 2025
EPS estimate -$0.470
EPS actual -$0.440
EPS Surprise 6.38%
Revenue estimate 4.48M
Revenue actual 11.23M
Revenue Surprise 150.67%
Jun 30, 2025
-$0.370 (2.63%)
Release date Aug 07, 2025
EPS estimate -$0.380
EPS actual -$0.370
EPS Surprise 2.63%
Revenue estimate 6.8M
Revenue actual 6.463M
Revenue Surprise -4.96%

Last 4 Quarters for C4 Therapeutics

Below you can see how CCCC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Beat
Release date Aug 07, 2025
Price on release $2.58
EPS estimate -$0.380
EPS actual -$0.370
EPS surprise 2.63%
Date Price
Aug 01, 2025 $2.12
Aug 04, 2025 $2.10
Aug 05, 2025 $2.01
Aug 06, 2025 $1.96
Aug 07, 2025 $2.58
Aug 08, 2025 $2.50
Aug 11, 2025 $2.42
Aug 12, 2025 $2.24
Aug 13, 2025 $2.33
4 days before 21.70%
4 days after -9.69%
On release day -3.10%
Change in period 9.91%
Sep 30, 2025 Beat
Release date Nov 06, 2025
Price on release $2.38
EPS estimate -$0.470
EPS actual -$0.440
EPS surprise 6.38%
Date Price
Oct 31, 2025 $2.61
Nov 03, 2025 $2.48
Nov 04, 2025 $2.26
Nov 05, 2025 $2.37
Nov 06, 2025 $2.38
Nov 07, 2025 $2.34
Nov 10, 2025 $2.34
Nov 11, 2025 $2.48
Nov 12, 2025 $2.48
4 days before -8.81%
4 days after 4.20%
On release day -1.68%
Change in period -4.98%
Dec 31, 2025 Beat
Release date Feb 26, 2026
Price on release $2.78
EPS estimate -$0.310
EPS actual -$0.180
EPS surprise 41.94%
Date Price
Feb 20, 2026 $2.16
Feb 23, 2026 $2.30
Feb 24, 2026 $2.39
Feb 25, 2026 $2.77
Feb 26, 2026 $2.78
Feb 27, 2026 $2.70
Mar 02, 2026 $3.17
Mar 03, 2026 $2.95
Mar 04, 2026 $3.09
4 days before 28.70%
4 days after 11.15%
On release day -2.88%
Change in period 43.06%
Mar 31, 2026 Beat
Release date May 12, 2026
Price on release $3.17
EPS estimate -$0.251
EPS actual -$0.200
EPS surprise 20.20%
Date Price
May 06, 2026 $2.93
May 07, 2026 $2.98
May 08, 2026 $2.95
May 11, 2026 $3.17
May 12, 2026 $3.17
May 13, 2026 $3.68
May 14, 2026 $3.63
May 15, 2026 $3.56
May 18, 2026 $3.22
4 days before 8.19%
4 days after 1.58%
On release day 16.09%
Change in period 9.90%

C4 Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for CCCC?
C4 Therapeutics Inc (CCCC) has scheduled its earnings report for Aug 06, 2026 before the markets open.

What is the CCCC price-to-earnings (P/E) ratio?
CCCC P/E ratio as of Jun 22, 2026 (TTM) is -5.04.

What is the CCCC EPS forecast?
The forecasted EPS (Earnings Per Share) for C4 Therapeutics Inc (CCCC) for the first fiscal quarter 2026 is -$0.230.

What are C4 Therapeutics Inc's retained earnings?
On its balance sheet, C4 Therapeutics Inc reported retained earnings of $6.20 million for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT C4 THERAPEUTICS INC
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma an...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE